Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Steven L. Chapman reported multiple sales of Common stock of NTRA via Form 144. The filing lists individual dispositions on 01/02/2026, 01/20/2026, 01/21/2026, 01/27/2026, 01/28/2026, and 02/02/2026, including a sale of 85,299 shares on 02/02/2026 for $19,679,798.82. The transactions are reported through Morgan Stanley Smith Barney LLC as broker.
Solomon Moshkevich reported a proposed sale of 3,000 performance shares under a Form 144 notice. The filing lists multiple recent dispositions of Common stock between 12/12/2025 and 02/02/2026, including transactions of 23,205, 4,692, and other lot sizes with dollar amounts shown.
The notice names Morgan Stanley Smith Barney LLC as the broker and identifies the securities class as Common. Timing and cash‑flow treatment for the proposed 3,000 performance shares are tied to the Form 144 filing process.
Natera, Inc. reports strong 2025 growth with total revenues of $2.31 billion, up from $1.70 billion in 2024, driven mainly by higher volumes and pricing in its Panorama, Horizon and Signatera testing businesses. The company processed about 3.53 million tests in 2025, up from 3.06 million in 2024, including a jump in oncology units from roughly 528,200 to 800,800.
Despite growth, Natera remained unprofitable, posting a 2025 net loss of $208.2 million versus a $190.4 million loss in 2024, with higher research and development and selling, general and administrative expenses. However, operating cash flow improved to $215.3 million, and the company ended 2025 with $1.08 billion in cash, cash equivalents and restricted cash and $80.3 million drawn on its UBS credit line. Natera also completed the acquisition of Foresight Diagnostics, recording a $335.3 million developed technology intangible asset that it values using discounted future cash flows.
Natera, Inc. reported strong growth for the fourth quarter and full year 2025. Total revenue reached $665.5 million in Q4 2025, up 39.8% from Q4 2024, and $2,306.1 million for 2025, a 35.9% increase over 2024, driven mainly by higher product revenues and better pricing.
The company processed about 3.53 million tests in 2025, with oncology test volumes rising 51.6% to roughly 800,800. Gross margin improved to 64.7% for 2025, up from 60.3% in 2024, as scale and cost efficiencies took hold.
Natera achieved positive cash inflow of approximately $107.6 million in 2025, while still posting a net loss of $208.2 million, or ($1.52) per diluted share. Management guides 2026 revenue to $2.62–$2.70 billion with gross margin of 63%–65% and expects positive net cash inflow.
T. Rowe Price Associates, Inc. reported beneficial ownership of 10,872,702 shares of Natera Inc. common stock, representing 7.8% of the class as of 12/31/2025. It has sole voting power over 10,475,212 shares and sole dispositive power over 10,871,989 shares.
The firm states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Natera. It also disclaims being the beneficial owner of the securities, despite filing this Schedule 13G/A amendment.
Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported several open‑market sales of Natera common stock. On February 2 and 3, 2026, he sold blocks of shares at weighted average prices ranging from about $228.50 to $234.00 per share.
The Form 4 shows individual transactions between 16 and 1,639 shares each, leaving 137,847 shares beneficially owned directly after the final sale. Most sales were made under a pre‑arranged Rule 10b5‑1 trading plan, and one 1,639‑share sale was executed to cover tax withholding on vesting RSUs.
Natera, Inc. CEO and President Steven Leonard Chapman reported multiple stock sales in early February 2026. On February 2 and 3, he sold several blocks of Natera common stock at weighted average prices generally between $228.50 and $234.00 per share, in open-market transactions.
The filing states that most sales on February 2 were made under a Rule 10b5-1 trading plan adopted on December 11, 2023 and amended on December 2, 2024, which automates trading according to preset instructions. A separate February 3 sale of 4,725 shares at a weighted average price of $230.768 was made to cover tax withholding tied to vesting restricted stock units. After these transactions, Chapman directly owned 123,156 shares of Natera common stock.
Natera, Inc. chief financial officer Michael Burkes Brophy reported multiple stock sales on February 3, 2026. He sold 1,268 shares of common stock at $230.768 per share to cover tax withholding tied to restricted stock unit vesting. He also sold 700 shares at a weighted average price of $225.2479 and 4,971 shares at a weighted average price of $227.447 under a Rule 10b5-1 trading plan adopted in 2025. After these transactions, he directly held 52,120 Natera shares.
Natera, Inc. executive John Fesko, its President and Chief Business Officer, reported two sales of Natera common stock on February 3, 2026. He sold 1,179 shares at $230.768 and 2,415 shares at $231.14, both reported as direct holdings.
According to the filing, each sale was made to satisfy tax withholding and remittance obligations from vesting restricted stock units and was executed under written instructions intended to meet Rule 10b5-1(c) affirmative defense conditions. After these transactions, Fesko directly beneficially owns 178,081 shares of Natera common stock.
Natera, Inc. director and co-founder Sheena Jonathan reported a small sale of company stock. On February 3, 2026, she sold 435 shares of Natera common stock at $230.768 per share. The sale was made to cover tax withholding and remittance obligations tied to the vesting of restricted stock units and was executed under a written instruction intended to meet Rule 10b5-1(c) affirmative defense conditions in her January 31, 2025 stock unit agreement.
After this transaction, Jonathan directly holds 263,161 shares of Natera common stock. In addition, 21,782 shares are held by Caraluna 1 Trust and 21,782 shares are held by Caraluna 2 Trust for the benefit of trust beneficiaries, and she disclaims beneficial ownership of those trust-held shares.